BridgeMD
New treatment option for Progressive Multiple Sclerosis
Official title Effects of Transcranial Static Magnetic Field Stimulation (tSMS) in Progressive Multiple Sclerosis
ClinicalTrials.gov ID: NCT05811013
What this study is testing
- What it's testing
- In multiple sclerosis (MS) brains, inflammation induces specific abnormalities of synaptic transmission, collectively called inflammatory synaptopathy. Such synaptopathy consists in unbalanced glutamatergic and GABAergic transmission and in remarkable changes in synaptic plasticity, causing excitotoxic neurodegeneration and impairing the clinical compensation of the ongoing brain damage, thereby exacerbating the clinical manifestation of the disease.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Ability to give written informed consent to the study
- Age range 18-65 years
- Diagnosis of primary of secondary progressive MS according to 2017 revised Macdonald's criteria (Thompson et al., 2017), presenting with signs of...
- EDSS ≤ 6,5
- Ability to participate to the study protocol
You likely can't join if
- Relapsing-remitting MS or progressive MS presenting with signs of symptoms other than those typical of the ascending myelopathy phenotype (i.e...
- Female with positive pregnancy test at baseline or having active pregnancy plans
- Comorbidities for which synaptic plasticity may be altered (i.e., Parkinson's disease, Alzheimer's disease, stroke)
- Contraindications to TMS
- History or presence of any unstable medical condition such as malignancy or infection
- Use of medications with increased risk of seizures (i.e. Fampridine, 4-Aminopyridine)
See the full eligibility criteria
- Ability to give written informed consent to the study
- Age range 18-65 years
- Diagnosis of primary of secondary progressive MS according to 2017 revised Macdonald's criteria (Thompson et al., 2017), presenting with signs of symptoms of progressive dysfunction of the corticospinal tract
- EDSS ≤ 6,5
- Ability to participate to the study protocol
- No or stable (at least six months) DMT or rehabilitative treatments before study entry, and willingness not to change these therapies (including cannabinoids, SSRI, baclofen) during the study.
- Relapsing-remitting MS or progressive MS presenting with signs of symptoms other than those typical of the ascending myelopathy phenotype (i.e. progressive cerebellar or cognitive involvement)
- Female with positive pregnancy test at baseline or having active pregnancy plans
- Comorbidities for which synaptic plasticity may be altered (i.e., Parkinson's disease, Alzheimer's disease, stroke)
- Contraindications to TMS
- History or presence of any unstable medical condition such as malignancy or infection
- Use of medications with increased risk of seizures (i.e. Fampridine, 4-Aminopyridine)
- Concomitant use of drugs that may alter synaptic transmission and plasticity (L-dopa, antiepileptics)
The study team makes the final eligibility decision.
Where it's taking place
- Pozzilli, Isernia, Italy
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Pozzilli, Isernia, Italy. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.